ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Clinical Use of Anabolics and Hormones
Clinical Use of Anabolics and Hormones
Video: Use of Tesamorelin to Decrease Abdominal Fat in HIV Patients
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 36993" data-attributes="member: 3"><p><strong>Steven K. Grinspoon, MD, </strong>professor of medicine at Harvard Medical School, discusses the molecular and clinical implications of visceral adipose tissue accumulation in lipodystrophy.</p><p>In his presentation, Grinspoon covered HIV lipodystrophy, which occurs in about 25% of HIV-infected patients. Initially, researchers focused on the drugs to treat the condition but have moved on to focusing on the HIV itself.</p><p>Grinspoon also touches on new treatment strategies that would focus on the development of a growth-hormone releasing hormone to selectively reduce visceral fat in HIV lipodystrophy.</p><p></p><p><a href="http://www.healio.com/endocrinology/cardiometabolic-disorders/news/online/%7Bc9d031cb-33c1-46a4-a49e-bdee1917c5fa%7D/video-new-treatment-strategy-in-the-making-for-hiv-lipodystrophy" target="_blank">http://www.healio.com/endocrinology/cardiometabolic-disorders/news/online/{c9d031cb-33c1-46a4-a49e-bdee1917c5fa}/video-new-treatment-strategy-in-the-making-for-hiv-lipodystrophy</a></p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 36993, member: 3"] [B]Steven K. Grinspoon, MD, [/B]professor of medicine at Harvard Medical School, discusses the molecular and clinical implications of visceral adipose tissue accumulation in lipodystrophy. In his presentation, Grinspoon covered HIV lipodystrophy, which occurs in about 25% of HIV-infected patients. Initially, researchers focused on the drugs to treat the condition but have moved on to focusing on the HIV itself. Grinspoon also touches on new treatment strategies that would focus on the development of a growth-hormone releasing hormone to selectively reduce visceral fat in HIV lipodystrophy. [url]http://www.healio.com/endocrinology/cardiometabolic-disorders/news/online/%7Bc9d031cb-33c1-46a4-a49e-bdee1917c5fa%7D/video-new-treatment-strategy-in-the-making-for-hiv-lipodystrophy[/url] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Clinical Use of Anabolics and Hormones
Clinical Use of Anabolics and Hormones
Video: Use of Tesamorelin to Decrease Abdominal Fat in HIV Patients
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top